These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 23195035)

  • 21. A recombinant 19 kDa Plasmodium berghei merozoite surface protein 1 formulated with alum induces protective immune response in mice.
    Wan Omar A; Roslaini AM; Ngah ZU; Azahari AA; Zahedi M; Baharudin O
    Trop Biomed; 2007 Jun; 24(1):119-26. PubMed ID: 17568385
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Protective immune responses elicited by immunization with a chimeric blood-stage malaria vaccine persist but are not boosted by Plasmodium yoelii challenge infection.
    Alaro JR; Lynch MM; Burns JM
    Vaccine; 2010 Oct; 28(42):6876-84. PubMed ID: 20709001
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenicity of a plasmid DNA vaccine encoding 42kDa fragment of Plasmodium vivax merozoite surface protein-1.
    Sheikh IH; Kaushal DC; Chandra D; Kaushal NA
    Acta Trop; 2016 Oct; 162():66-74. PubMed ID: 27311385
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adenovectors induce functional antibodies capable of potent inhibition of blood stage malaria parasite growth.
    Bruder JT; Stefaniak ME; Patterson NB; Chen P; Konovalova S; Limbach K; Campo JJ; Ettyreddy D; Li S; Dubovsky F; Richie TL; King CR; Long CA; Doolan DL
    Vaccine; 2010 Apr; 28(18):3201-10. PubMed ID: 20188680
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A single injection of 19 kda carboxy-terminal fragment of Plasmodium yoelii merozoite surface protein 1 (PyMSP1(19)) formulated with Montanide ISA and CpG ODN induces protective immune response in mice.
    Hirunpetcharat C; Mahakunkijcharoen Y; Jeamwattanalert P; Kittigul L; Mahannop P; Pichyangkul S
    Asian Pac J Allergy Immunol; 2011 Sep; 29(3):252-9. PubMed ID: 22053595
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A recombinant baculovirus 42-kilodalton C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 protects Aotus monkeys against malaria.
    Chang SP; Case SE; Gosnell WL; Hashimoto A; Kramer KJ; Tam LQ; Hashiro CQ; Nikaido CM; Gibson HL; Lee-Ng CT; Barr PJ; Yokota BT; Hut GS
    Infect Immun; 1996 Jan; 64(1):253-61. PubMed ID: 8557348
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Synthetic Nanoparticle Based Vaccine Approach Targeting MSP4/5 Is Immunogenic and Induces Moderate Protection Against Murine Blood-Stage Malaria.
    Wilson KL; Pouniotis D; Hanley J; Xiang SD; Ma C; Coppel RL; Plebanski M
    Front Immunol; 2019; 10():331. PubMed ID: 30930890
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase 1 trial of PfCP2.9: an AMA1/MSP1 chimeric recombinant protein vaccine for Plasmodium falciparum malaria.
    Malkin E; Hu J; Li Z; Chen Z; Bi X; Reed Z; Dubovsky F; Liu J; Wang Q; Pan X; Chen T; Giersing B; Xu Y; Kang X; Gu J; Shen Q; Tucker K; Tierney E; Pan W; Long C; Cao Z
    Vaccine; 2008 Dec; 26(52):6864-73. PubMed ID: 18930094
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunogenicity of novel nanoparticle-coated MSP-1 C-terminus malaria DNA vaccine using different routes of administration.
    Cherif MS; Shuaibu MN; Kurosaki T; Helegbe GK; Kikuchi M; Yanagi T; Tsuboi T; Sasaki H; Hirayama K
    Vaccine; 2011 Nov; 29(48):9038-50. PubMed ID: 21939717
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Production, characterisation and immunogenicity of a plant-made Plasmodium antigen--the 19 kDa C-terminal fragment of Plasmodium yoelii merozoite surface protein 1.
    Ma C; Wang L; Webster DE; Campbell AE; Coppel RL
    Appl Microbiol Biotechnol; 2012 Apr; 94(1):151-61. PubMed ID: 22170105
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prediction of merozoite surface protein 1 and apical membrane antigen 1 vaccine efficacies against Plasmodium chabaudi malaria based on prechallenge antibody responses.
    Lynch MM; Cernetich-Ott A; Weidanz WP; Burns JM
    Clin Vaccine Immunol; 2009 Mar; 16(3):293-302. PubMed ID: 19116303
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunization against Plasmodium chabaudi malaria using combined formulations of apical membrane antigen-1 and merozoite surface protein-1.
    Burns JM; Flaherty PR; Romero MM; Weidanz WP
    Vaccine; 2003 May; 21(17-18):1843-52. PubMed ID: 12706668
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetic linkage of autologous T cell epitopes in a chimeric recombinant construct improves anti-parasite and anti-disease protective effect of a malaria vaccine candidate.
    Singh B; Cabrera-Mora M; Jiang J; Galinski M; Moreno A
    Vaccine; 2010 Mar; 28(14):2580-92. PubMed ID: 20097151
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Generation, characterization and immunogenicity of a novel chimeric recombinant protein based on Plasmodium vivax AMA-1 and MSP1
    Rocha MV; Françoso KS; Lima LC; Camargo TM; Machado RLD; Costa FTM; Rénia L; Nosten F; Russell B; Rodrigues MM; Soares IS
    Vaccine; 2017 Apr; 35(18):2463-2472. PubMed ID: 28341111
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gamma interferon levels and antibody production induced by two PvMSP-1 recombinant polypeptides are associated with protective immunity against P.vivax in Aotus monkeys.
    Barrero CA; Delgado G; Sierra AY; Silva Y; Parra-Lopez C; Patarroyo MA
    Vaccine; 2005 Jul; 23(31):4048-53. PubMed ID: 15893858
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and immunogenicity of a malaria vaccine, Plasmodium falciparum AMA-1/MSP-1 chimeric protein formulated in montanide ISA 720 in healthy adults.
    Hu J; Chen Z; Gu J; Wan M; Shen Q; Kieny MP; He J; Li Z; Zhang Q; Reed ZH; Zhu Y; Li W; Cao Y; Qu L; Cao Z; Wang Q; Liu H; Pan X; Huang X; Zhang D; Xue X; Pan W
    PLoS One; 2008 Apr; 3(4):e1952. PubMed ID: 18398475
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pre-clinical evaluation of the malaria vaccine candidate P. falciparum MSP1(42) formulated with novel adjuvants or with alum.
    Pichyangkul S; Gettayacamin M; Miller RS; Lyon JA; Angov E; Tongtawe P; Ruble DL; Heppner DG; Kester KE; Ballou WR; Diggs CL; Voss G; Cohen JD; Walsh DS
    Vaccine; 2004 Sep; 22(29-30):3831-40. PubMed ID: 15364429
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination of protein and viral vaccines induces potent cellular and humoral immune responses and enhanced protection from murine malaria challenge.
    Hutchings CL; Birkett AJ; Moore AC; Hill AV
    Infect Immun; 2007 Dec; 75(12):5819-26. PubMed ID: 17908809
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of humoral immune responses elicited by DNA and protein vaccines based on merozoite surface protein-1 from Plasmodium yoelii, a rodent malaria parasite.
    Kang Y; Calvo PA; Daly TM; Long CA
    J Immunol; 1998 Oct; 161(8):4211-9. PubMed ID: 9780195
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Construction and expression of Plasmodium berghei chimeric protein in Pichia pastoris and its immunogenicity in mice].
    Cao Y; Zhang DM; Pan WQ
    Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 2008 Oct; 26(5):327-31. PubMed ID: 19157293
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.